Advertisement
Indian
India ranks high in Cyber security ranking:MeitY official
Congratulating the technical stakeholders for improved cyber...
Bajaj Allianz General now the 4th insurer to offer drone cover
Insurance protection is offered for the damage to the drone and the...
Govt has identified 101 projects under PM Gati Shakti National Master Plan: Sarbananda Sonowal
Sarbananda Sonowa,Union Minister, Ministry of Ports, Shipping and...
Investment via P-notes hit 43-month high in OcT
According to Securities and Exchange Board of India data, the value...
International
Covid-19 Pandemic:World’s top 100 most valuable insurers could lose $100bn in brand value
At the time of Covid-19 Pandemic, insurance firms damaged both financially and reputationally, as they face a surge in coronavirus-related claims and risk angering customers if they refuse to pay out.Chinese brands make up half of the top 10 insurance companies, while Allianz and Axa also rank among the most valuable firms.
“The Covid-19 pandemic is going to hit the insurance sector hard – Brand Finance has predicted that insurance brands could face up to a 20 per cent drop in brand value and undoubtedly, we are going to witness revenue slowdown for all brands across the sector,” said Brand Finance chief executive David Haigh.
International tourism could decline by 60-80 per cent in 2020: UN
Arrivals in March dropped sharply by 57 per cent following the start of a lockdown in many countries, as well as the widespread introduction of travel restrictions and the closure of airports and national borders. This translates into a loss of 67 million international arrivals and about USD 80 billion in receipts (exports from tourism).
Covid-19 Pandemic:Insurers to see erase profits until 2021 second half, says Fitch
Gilead ties up with Indian phrma cos for COVID-19 drug supply
The countries consist of nearly all low-income and lower-middle income ones, as well as several that are upper-middle- and high-income, the drugmaker said. Afghanistan, India, North Korea, Pakistan and South Africa are among the countries.
The licensees will also set their own prices for the generic product they produce, Gilead said.
The licenses are royalty-free until the World Health Organization declares the end of the public health emergency regarding COVID-19, or until a product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, the company said.
Briefs
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Events
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Articles
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Features
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Data
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Interviews
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Facts
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.